Melanoma: predicting immunotherapy-induced side effects
Increased gene activity in the SYK pathway could be the basis of a blood test to identify melanoma patients most susceptible to severe side effects.
List view / Grid view
Increased gene activity in the SYK pathway could be the basis of a blood test to identify melanoma patients most susceptible to severe side effects.
The discovery that genomic deletions cause altBRAFs can help develop new therapies to overcome drug resistance in BRAF-mutant melanoma.
In this Q&A, esteemed Dr Rhoda Alani discusses the epigenetic landscape of therapy resistant melanomas and elucidates how corin treatment impacts the reprogramming of melanoma cell phenotypes. The findings suggest a new treatment paradigm for melanoma which could also be relevant to targeted therapy resistance mechanisms for other cancer types.
Using bioinformatics analyses, HK-CREs impact on cellular processes was studied, including their potential as housekeeping tumour suppressors.
Carboxylic nanodiamonds could be a therapeutic agent for cancer, as melanoma cells treated with them showed little to no metastasis.
Important step achieved by US researchers as stable and potent immune therapy delivery system eradicates tumours in mouse models of melanoma, colon, and breast cancer, while preventing the formation of future tumour.
A combination of radiotherapy followed by immunotherapy is a promising strategy for the treatment of oral malignant melanomas in dogs.
US study uncovers the best way to treat recurrent or progressive brain metastases using an amino acid PET technique.
Results show the number of specialised immune cells available for fighting skin cancer doubled when a new treatment blocked their escape from melanoma tumours.
Japanese researchers reported that a key transcription factor “Nrf3” regulates the process of melanin production in mouse and human cells.
After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
Researchers have developed a two-step approach using whole exome sequencing to focus on genes and pathways that predict whether cancer patients will respond to immunotherapy.
Scientists have demonstrated how killer T cells used in immunotherapy to eliminate cancer cells can also destroy tumour lymphatic vessels, thus greatly reducing the risk of metastasis.
A new biodegradable gel can release drugs and special antibodies that simultaneously deplete macrophages from the surgical site and activate T cells.
A new study from the University of Michigan Rogel Cancer Center, US has revealed that a cytokine and a fatty acid can work together to trigger ferroptosis. Here, Dr Weiping Zou, the lead researcher from the study, outlines how this process could be used to target cancer cells and enhance immunotherapies.